Quote | Qualigen Therapeutics Inc. (NASDAQ:QLGN)
Last: | $0.2905 |
---|---|
Change Percent: | -1.01% |
Open: | $0.3 |
Close: | $0.2905 |
High: | $0.319 |
Low: | $0.2905 |
Volume: | 9,216 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
News | Qualigen Therapeutics Inc. (NASDAQ:QLGN)
JUPITER, FL, April 16, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics, Inc. (“Qualigen”) (NASDAQ: QLGN ) to a...
Poster Includes Preclinical Data on Novel Direct Pan-RAS Inhibitors CARLSBAD, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN) today announces a poster presentation on its preclinical No...
Message Board Posts | Qualigen Therapeutics Inc. (NASDAQ:QLGN)
Subject | By | Source | When |
---|---|---|---|
and now down 18%. Form S 3 effect | chrislal | investorshub | 01/09/2023 8:30:45 PM |
$QLGN: BOooommmmmmmmmmm....... now 1.85 | makinezmoney | investorshub | 01/09/2023 7:54:44 PM |
znewcar1: QLGN 52% v50,8M c.9268 f35,3M H1.52 off the .557 | znewcar1 | investorshangout | 04/13/2022 3:01:33 AM |
Looking like something is brewing again, that could | trendzone | investorshub | 12/28/2021 6:32:10 PM |
Sure would be nice if it did a | trendzone | investorshub | 12/27/2021 1:02:45 PM |
News, Short Squeeze, Breakout and More Instantly...
Qualigen Therapeutics Inc. Company Name:
QLGN Stock Symbol:
NASDAQ Market:
JUPITER, FL, April 16, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics, Inc. (“Qualigen”) (NASDAQ: QLGN ) to a...
Poster Includes Preclinical Data on Novel Direct Pan-RAS Inhibitors CARLSBAD, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN) today announces a poster presentation on its preclinical No...
CARLSBAD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or the “Company,” Nasdaq: QLGN) today announces that a poster featuring its early clinical experience with a novel first-in-class G-Quadruplex experimental anti-cancer drug, ...